NRX Pharmaceuticals
NRXP
18 hedge funds and large institutions have $39.2M invested in NRX Pharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 9 increasing their positions, reducing their positions, and 1 closing their positions.
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
69% more capital invested
Capital invested by funds: $23.1M → $39.2M (+$16.1M)
20% more funds holding
Funds holding: 15 → 18 (+3)
19% more ownership
Funds ownership: 26.34% → 45.34% (+19%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFM
Boothbay Fund Management
New York
|
+$5.26M |
| 2 |
BI
Bulldog Investors
Saddle Brook,
New Jersey
|
+$2.45M |
| 3 |
WCMNY
Westchester Capital Management (New York)
Valhalla,
New York
|
+$2.39M |
| 4 |
WAM
Weiss Asset Management
Boston,
Massachusetts
|
+$2M |
| 5 |
KIM
Karpus Investment Management
Pittsford,
New York
|
+$1.56M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$120K |
NRXP Hedge Fund Activity: Q1 2018 in Review
18 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in NRX Pharmaceuticals (NRXP) for Q1 2018, worth a combined $39.2M — up 69% from $23.1M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new NRXP positions and 1 closed out — a net gain of 3 holders — while 9 added to existing stakes and 0 trimmed.
The largest buyer was Boothbay Fund Management, opening a new position worth an estimated $5.26M. The largest seller was Virtu Financial, exiting entirely with an estimated $120K sold.
- 18 institutional investors held NRX Pharmaceuticals (NRXP) as of Q1 2018, up from 15 in Q4 2017.
- Funds reported $39.2M of NRX Pharmaceuticals stock for Q1 2018, up 69% quarter-over-quarter.
- 4 funds opened new NRX Pharmaceuticals positions in Q1 2018 and 1 closed out, a net change of +3 holders.
- The largest NRX Pharmaceuticals buyer in Q1 2018 was Boothbay Fund Management, an estimated $5.26M added.
- The largest NRX Pharmaceuticals seller in Q1 2018 was Virtu Financial, an estimated $120K sold.
Based on aggregated 13F filings for Q1 2018.